The long-term outcomes of mepolizumab treatment at 100 mg dose on idiopathic chronic eosinophilic pneumonia: A real-life experience.

MLA

Vural Solak, Gurgun Tugce, et al. “The Long-Term Outcomes of Mepolizumab Treatment at 100 Mg Dose on Idiopathic Chronic Eosinophilic Pneumonia: A Real-Life Experience.” Allergy and Asthma Proceedings, vol. 45, no. 4, July 2024, pp. e46–53. EBSCOhost, https://doi.org/10.2500/aap.2024.45.240029.

APA

Vural Solak, G. T., Aksu, K., Akkale, O., Telli, O., Celik Tuglu, H., Dindar Celik, F., & Yagdiran, M. (2024). The long-term outcomes of mepolizumab treatment at 100 mg dose on idiopathic chronic eosinophilic pneumonia: A real-life experience. Allergy and Asthma Proceedings, 45(4), e46–e53. https://doi.org/10.2500/aap.2024.45.240029

Chicago

Vural Solak, Gurgun Tugce, Kurtulus Aksu, Ozgur Akkale, Onur Telli, Hatice Celik Tuglu, Fatma Dindar Celik, and Melis Yagdiran. 2024. “The Long-Term Outcomes of Mepolizumab Treatment at 100 Mg Dose on Idiopathic Chronic Eosinophilic Pneumonia: A Real-Life Experience.” Allergy and Asthma Proceedings 45 (4): e46–53. doi:10.2500/aap.2024.45.240029.